Corvus Pharmaceuticals financials
$11.76−0.93%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — | — | — |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$43.0M | -$27.5M | -$23.4M | -$32.6M | -$38.6M | -$6.3M | -$48.9M | -$49.2M | -$56.5M | -$37.0M |
| Net income | -$15.3M | -$62.3M | -$27.0M | -$41.3M | -$43.2M | -$6.0M | -$46.7M | -$46.9M | -$55.7M | -$36.4M |
| Net margin | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.53 | $-1.02 | $-0.56 | $-0.89 | $-1.03 | $-0.20 | $-1.59 | $-1.71 | $-2.72 | $-2.36 |
| EBITDA | -$42.9M | -$27.5M | -$23.3M | -$32.2M | -$38.2M | -$43.1M | -$48.8M | -$49.0M | -$55.9M | -$35.7M |
| Operating cash flow | -$32.8M | -$25.4M | -$23.9M | -$27.0M | -$36.7M | -$34.8M | -$37.3M | -$41.0M | -$46.2M | -$27.9M |
| Free cash flow | -$33.0M | -$25.4M | -$24.0M | -$27.3M | -$36.7M | -$34.9M | -$37.3M | -$41.3M | -$46.5M | -$30.1M |
| Diluted shares | 79.7M | 61.0M | 48.0M | 46.6M | 41.9M | 29.5M | 29.3M | 27.5M | 20.5M | 15.4M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $4.6M | $8.7M | $12.6M | $13.2M | $63.5M | $16.5M |
| Short-term investments | $52.2M | $43.2M | $14.5M | $29.1M | $6.0M | $27.8M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $71.1M | $68.9M | $45.6M | $68.2M | $109.5M | $85.5M |
| Total liabilities | $9.9M | $36.3M | $6.9M | $12.1M | $12.3M | $13.4M |
| Shareholders' equity | $61.2M | $32.6M | $38.7M | $56.1M | $97.2M | $72.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology